Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Xenetic Biosciences (XEN)

  Print      Mail a friend

Wednesday 04 January, 2012

Xenetic Biosciences

Acquisition of SymbioTec Update

RNS Number : 9426U
Xenetic Biosciences PLC
04 January 2012


Xenetic Biosciences PLC
('Xenetic' or the 'Company')


Closing Update Re: the proposed Acquisition of SymbioTec GmbH; arrangements with Serum Institute of India and proposed Open Offer

Xenetic Biosciences plc (AIM: XEN.L), the bio-pharmaceutical company specialising in the development of high-value differentiated biologic drugs and vaccines, announces an update in relation to completion of the Proposals set out in the Shareholder Circular of 4 August 2011 (the "Circular"), and as approved by shareholders at the Company's General Meeting held on 2 September 2011. Defined terms in this announcement shall have the meanings given to them in the Circular unless the context requires otherwise. 

The Company recently announced that completion of the acquisition of SymbioTec GmbH ("SymbioTec") ("the Acquisition") was expected to occur by no later than 31 December 2011.  This has not proved possible, inter alia as a result of certain new disclosures that have been made by the Sellers in relation to warranties to be given at Completion, and in relation to the conduct of SymbioTec's affairs since 4 August 2011.  These include continuing uncertainty as to the establishment of satisfactory arrangements concerning the entitlements under German law of various individuals and ex-employees (co-inventors of the Bis-met histone technology platform) as regards future revenue streams arising from the technology platform. 

The Company is working to achieve a commercially acceptable solution to the above, but to date a result that satisfies the Company has not been achieved.  Consequently, and with a view to bringing to a close the protracted efforts of all parties to the proposed Acquisition, the Xenetic Board has informed the Sellers that, unless final terms satisfactory to the Company are concluded by no later than close of UK business on 16th January 2012, the Acquisition process will be terminated. While the Company is hopeful that a satisfactory outcome can be achieved it will maintain a robust stance on the matter and reserves all of its rights under the Sale and Purchase Agreement.

One consequence of the foregoing is that the Company therefore now expects to conclude all of its proposed arrangements with the Serum Institute of India ("SIIL") under the Master Agreement (et al) by no later than 20th January 2012.  These include legal completion of the new Master Agreement (on which date Xenetic will issue as fully paid 9 million New Ordinary Shares) as well as SIIL's subscription for a further 2.5m New Ordinary Shares to be issued at a price of 11 pence per share (representing a premium of 31.2% based on the mid-market closing price of a Xenetic Ordinary Share on 3rd January 2012) thereby raising £275,000 of new capital for the Company.

With respect to the proposed Open Offer, the Company will monitor near term market conditions prevailing after completion of First Closing (that is, after either the earlier of completion of the Acquisition of SymbioTec or the termination of the Sale and Purchase Agreement), particularly as respects the Ordinary Share price, thereby to determine whether the Open Offer should be pursued.

Further announcements will be made in due course.


Xenetic Biosciences plc
+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer


Singer Capital Markets (NOMAD & Broker)
+44 (0)20 3205 7500

Claes Spång


Walbrook PR
Paul McManus
Paul Cornelius



This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t